Gold prices steady ahead of Fed decision; weekly weakness noted
Investing.com -- Hyperfine, Inc. (NASDAQ:HYPR) stock climbed 4.6% following the announcement of promising early results from its CARE PMR study presented at the 2025 Alzheimer’s Association International Conference in Toronto.
The health technology company reported that its Swoop® system, an FDA-cleared AI-powered portable MRI system for the brain, achieved 100% sensitivity in detecting mild to moderate ARIA-E (cerebral edema) in Alzheimer’s patients undergoing Lecanemab therapy. The interim results came from 31 patients at Washington University School of Medicine in St. Louis, where participants were scanned using the Swoop® system within one week of their clinical high-field MRI scans.
The findings suggest that Hyperfine’s portable MRI technology could help address significant barriers to the regular MRI safety monitoring required for patients receiving amyloid-targeting therapies like Lecanemab and Donanemab. Conventional MRI systems often present challenges including high costs, scheduling delays, and logistical difficulties for patients and caregivers.
Dr. Tammie Benzinger, principal investigator of the study, indicated plans to expand the project to include community sites offering infusion therapy for early Alzheimer’s disease, noting that "this research could help alleviate the burden on families and facilities and improve overall access to care."
The CARE PMR study, funded by the Alzheimer’s Association and the American Society of Neuroradiology, is collecting data from multiple sites to assess the clinical utility and workflow benefits of using the Swoop® system to detect amyloid-related imaging abnormalities in Alzheimer’s patients receiving amyloid-targeting therapy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.